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378 Saliva sodium and chloride levels: a useful tool for
cystic ﬁbrosis (CF) diagnosis?
A.C. Gonc¸alves1, R.M.H. Mendonc¸a2, J.D. Ribeiro3, A.F. Ribeiro3, M.A. Ribeiro3,
I.A. Paschoal4, C.E. Levy1. 1University of Campinas UNICAMP Brazil, Clinical
Pathology, Campinas, Brazil; 2Centro Infantil Boldrini, Odonthology, Campinas,
Brazil; 3University of Campinas UNICAMP Brazil, Pediatrics, Campinas, Brazil;
4University of Campinas UNICAMP Brazil, Clinical Medicine, Campinas, Brazil
Objective: To compare biochemical parameters of saliva from CF patients and
healthy individuals.
Method: A cross sectional study including saliva samples of 42 CF patients from
the Pediatric CF Reference Center of University Hospital of Campinas SP Brazil
(UNICAMP) and 35 healthy individuals as controls. Saliva was collected with
Salivet® (Sardest-Germany) cotton roll, chewed for a minute. The amount of
saliva was measured and pH and concentrations of bicarbonate, sodium, chloride,
potassium, glucose, calcium and lactate, were determined by ABL mod 835
Radiometer ® (Denmark). Student’s T and Mann Whitney tests were used for
statistical analysis. The project was approved by the Research Ethics Committee.
Results: the mean age of samples was 15.03 years (± 6.92 years). Among
individuals with CF the mean age was 12.3 years (± 7.02 years) and in the
controls, 18.2 (±5.24 years). Statistically signiﬁcant difference between the two
groups was observed for the variables: bicarbonate (p< 0.001), sodium (p = 0.000),
chlorine (p = 0.03) and volume (p = 0.000). Averages of these variables in CF
and control group, respectively, were: bicarbonate (4. 72mmol/L; 1. 40mmol/L)
sodium (20.75mmol/L; 10.50mmol/L), chloride (30.41mmol/L; 23.18mmol/L) and
volume (19.32ml; 54.66ml). No statistically signiﬁcant difference was observed
between the groups for pH, potassium, calcium, lactate and glucose.
Conclusion: Some biochemical salivary parameters seem to be inﬂuenced by CF.
Other studies are necessary to conﬁrm the usefulness of saliva as complementary,
fast and inexpensive tool for CF diagnosis.
379 Utilization and healthcare charges in an insured US cystic
ﬁbrosis (CF) patient population
M.S. Broder1, S.Z. Nasr2, E. Chang1, K.F. Villa3. 1Partnerhsip for Health Analytic
Research, LLC, Beverly Hills, United States; 2University of Michigan Health
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Objective: To describe resource use, charges and medication adherence in
US CF patients.
Methods: This retrospective analysis used a US insurance claims data set. CF
patients were assigned an index date based on their ﬁrst claim for dornase alfa (DA)
(Pulmozyme) between 2006–2008. Included patients had 1 DA claim and were
continuously enrolled in the health insurance plan 2 years. They were excluded
if they had no claims for CF or had age <4. Patient characteristics over the 1-year
preindex period and adherence to DA in the 1-year postindex period were examined.
Results: The ﬁnal study included 934 patients. Mean age was 19.6 years
(SD 11.6) and 49.0% were female. The specialties seen most frequently were
pulmonology (35.5%) and primary care (29.4%). The cohort had a mean of
2.3 comorbid chronic conditions (SD 1.3), the most common were pancreatic
insufﬁciency (80.8%), P. aeruginosa (77.4%), chronic sinusitis (24.0%), and di-
abetes (17.2%). Frequently used medications were inhaled antibiotics (58.0%),
inhaled steroids (54.4%), and hypertonic saline (21.1%). 175 patients (18.7%)
were hospitalized for respiratory exacerbations; mean length of stay was 13.9 days.
Mean per patient annual healthcare charges were $51,155 (SD 56,849) and charges
related to respiratory exacerbations were $10,295 (SD 33,343). The mean adherence
(medication possession ratio) to DA in the postindex period was 0.59 (SD 0.30,
median 0.58).
Conclusion: Resource use and healthcare charges are high in patients with CF,
and adherence to dornase alfa is low. Future analyses will examine the relationship
between medication adherence and subsequent health and economic outcomes.
380 Cystic ﬁbrosis in Libya: the experience of an international
collaboration project
T. Repetto1, G. Mergni2, S. Zuffo2, N. Elgheriani3, K. Ettumi3. 1Meyer Children
Hospital, Pediatric, Florence, Italy; 2Meyer Children Hospital, Florence, Italy;
3Zahara Hospital, Zahara, Libyan Arab Jamahiriya
Background: There are as yet no data about cystic ﬁbrosis (CF) in Libya as a
CF center did not exist in this country until 2008. In 2008 a CF Center started in
accordance with an international collaboration between the CF Center of the Meyer
Hospital and the Zahra Hospital (ZH).
Methods: According the agreement, ZH acquired facilities in performing sweat
test, pancreatic and pulmonary function tests and microbiological colture. Doctor
and physiotherapist were trained and started a management plan. Patients were
regularly followed up; pharmacological and medical treatments were assured by
Lybian Governement.
Results: From July 2008 to December 2010, 31 patients were diagnosed of CF.
Seventy percent were the product of consanguineous marriages 42% had other
family members who also had CF (siblings) and in one family, more than two.
Up to now 31 CF patients (14 females, 17 males) are regularly followed up at the
Zahra Hospital). The mean age of patients was 8.9 yr (range 1−30 yr, median 7
yr) report; 15 were diagnosed outside of Libya, requiring the family to go abroad.
The most commonly visited foreign country was Tunisia followed by Germany
and Italy. Symptoms at presentation were respiratory and gastrointestinal in 75%.
Dehydration was the ﬁrst symptom in 20% and was severe enough to require
multiple hospitalizations in the ﬁrst years of life in 25% patients.
Between July, 2008 and February, 2010, the mean number of follow-up visits/patient
was 6.5.
Discussion: Our short experience in the ZH shows that families demonstrated good
compliance, coming regularly for check-up and thus avoiding having to go to a
foreign country for diagnosis and follow-up.
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Background: One supposed beneﬁt of prospective registration of clinical trials
is that it should discourage selective or delayed reporting of trials. We aimed to
determine the proportion of registered clinical trials involving participants with
cystic ﬁbrosis that are published and how soon after study completion publication
occurs.
Methods: In Jan 2011, we searched the register ClinicalTrials.gov for clinical trials
involving participants with cystic ﬁbrosis that were registered in January 2000 or
later and that were completed by December 2008. For each trial identiﬁed, we
searched Google Scholar using the names of the investigators and key terms for the
study population and intervention to determine whether the trial had been published
by the end of 2010.
Results: 240 trials involving participants with cystic ﬁbrosis had been registered
since 1999. Of these, 100 trials were reported on the register as having been
completed by December 2008. Of the 100 completed trials, 64 had been published
by December 2010. Of the remainder, 3 had been published as abstracts only and
2 had published secondary reports only, while 31 appeared unpublished. Among
the 64 published trials, the mean period between completion and publication was
28 months (SD 21). The number of trials that were published within 2 years of
their completion was 32.
Conclusion: Despite lodgement on a public register, many clinical trials in cystic
ﬁbrosis remain unpublished long after completion of the study. Half of those that
are published are not published within 2 years of study completion.
